Latest Us Market News

Nova Eye Medical has reported a record A$29.2 million revenue for FY25, driven by strong sales growth and improved profitability in its glaucoma segment. The company targets breakeven EBITDA in the first half of FY26 alongside continued cash flow improvements.

Change Financial Limited reported a record Q4 FY25 revenue of US$4.0 million, marking a 26% year-on-year increase, alongside positive underlying EBITDA and a strong outlook for FY26.

Nova Eye Medical has reported a record A$29.2 million revenue for FY25, driven by strong sales growth and improved profitability in its glaucoma segment. The company targets breakeven EBITDA in the first half of FY26 amid promising regulatory and market developments.

LTR Pharma has initiated commercial distribution of its nasal spray SPONTAN through Australia's Symbion pharmacy network and is advancing ROXUS development for a US launch in early 2026, while expanding its pipeline with a new intranasal treatment for swallowing disorders.

EZZ Life Science Holdings marked a pivotal quarter with the launch of its EZZDAY brand in the US, a significant Southeast Asia distribution agreement, and expanded domestic retail presence, driving a 46% jump in customer receipts.

Adveritas Limited reports a robust 62% increase in annualised recurring revenue to $10.47 million and a record doubling of full-year cash receipts, backed by a strategic $8.5 million institutional placement to accelerate growth in the US and new verticals.

Peninsula Energy advances commissioning at its Lance uranium project, resets most sales contracts to reduce risk, and secures a $15 million debt facility to support production ramp-up.

Bubs Australia has appointed Joe Coote as its new CEO, bringing extensive international FMCG and dairy leadership to spearhead its global growth ambitions in infant nutrition.

PainChek Limited has raised A$7.5 million through a strongly supported placement to accelerate its US market entry following anticipated FDA clearance and expand its innovative AI pain assessment technology internationally.

Bubs Australia Limited reports a strong FY25 with 29% revenue growth to $102.5 million, positive EBITDA turnaround, and sustained cash flow improvements. The company also advances its US market ambitions with a key FDA submission underway.

AML3D has appointed Arc Additive as its UK and European distribution partner, marking a strategic push into key manufacturing and defence markets across Europe. This move follows a successful capital raise and a contract with BAE Systems UK, underpinning AML3D’s growth ambitions.

Pureprofile Limited reported record FY25 results, achieving 19% revenue growth and launching new AI-driven data solutions to fuel future expansion.